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Abstract 
B6.C-H-2 ba [H (z l ) ]  is a mutant  derived from C57BL/6. The two strains 
mutually reject their skingrafts and are incompatible in the mixed leucocyte reaction 
(MLR) and in cell-mediated lympholysis (CML) assays. They are serologically 
indistinguishable. 
This report  shows that H(z l )  carries a new, private K end CML specificity 
clearly distinguishable from that of B6 by a third par ty strain, HTG. Antisera directed 
against the private H-2K specificity of  B6 present on H(z l )  cells) can block CML 
between the two strains in either direction. The new CML specificities of H(z l )  
cross-react with (public) CML specificities controlled by both K and D regions of 
other unrelated haplotypes.  The results suggest that H(z l )  carries a muta t ion  in the 
H-2K locus itself or in a closely linked gene, the product  of  which is also physically 
associated with the H-2K molecule corresponding to the cis-configuration of  the 
alleles in both loci. 
These findings indicate that T- and B-cell dictionaries for his tocompat ibi l i ty  
determinants are different. 
Introduction 
When a leucocyte population from peripheral blood,  spleen, or lymph nodes 
(responder = R) is, in an in vitro mixed culture system, sensitized with leucocytes from 
3On leave of absence from the Instituto di Genetic Medica, Universita di Torino, Torino, 
Italy. 
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a donor (stimulator = S) carrying a different haplotype at its major histocompatibility 
complex (MHC) then, in the responder population thymus-derived lymphocytes give 
rise to killer cells. These are able to recognize specifically and to lyse target cells sharing 
an MHC haplotype with the stimulator cell. Such systems can be viewed as candidates 
for in vitro models of allograft rejection (for review see Cerottini and Brunner 1973). 
In studies on the genetic control of induction and effector phase of this type of 
cell-mediated cell lysis, the most widely used assay for cell destruction employs 
s iCr.labeled PHA-stimulated leucocyte populations as targets. These are exposed for 
not more than 4-6 hours to the putative killer cells. This particular variant of cell- 
mediated cell lysis is called cell-mediated lympholysis (CML) (Lightbody et al. 1971). 
A number of reports from different laboratories show that in the mouse the 
determinants detected by the killer ceils in CML (CML-determinants) are controlled by 
loci very closely linked or identical with the H-2K and H-2D loci controlling the sero- 
logically def'med ubiquitous major histocompatibility antigens of this species (Alter 
et al. 1973, Abbasi et al. 1973, Nabholz et al. 1974). This interpretation is based on 
comparison of the results obtained with different combinations of responder, stimulator, 
and targets (T) involving congenic and noncongenic inbred strains carrying a variety 
of recombinant H-2 haplotypes. The results suggest, but do not prove, that CML- 
determinants are identical with the (H-2K and H-2D) molecules that carry the classical 
H-2 specificities. Further evidence suggesting identity came from studies employing 
hyperimmune anti-H-2 sera with defined specificity (Nabholz et al. 1974). Such sera 
were found to block CML only when they are directed against the H-2K or H-2D 
incompatibility against which the killer is active. (In particular, sera directed 
against immune response region associated (Ia-) antigens have no blocking activity in 
CML; M. Nabholz, unpublished results). 
(The only findings that seem incompatible with identity of CML, with H-2K, 
and H-2D determinants are those o'f Edidin and Henny (1973) who found that capping 
with polyspecific sera probably directed mainly against H-2 antigens could remove all 
antigens as detected by immunofluorescence and complement mediated lysis without 
impairing the susceptibility of capped targets to cell-mediated lysis. Barring proof to the 
contrary, we feel that their data are likely to reflect different requirements of various 
assay systems with regard to the number of H-2 molecules on the target cell.) 
If the CML loci are not identical with the H-2K and H-2D genes, then an ex- 
planation of the accumulated data requires either a) that not only the CML genes but 
also their products are very closely associated with H-2K and H-2D genes or products, 
respectively, the latter association corresponding to the coupling phase of the alleles 
involved; or b) that anti-H~2 sera generally contain undetected noncomplement 
binding blocking antibodies directed against CML determinants. 
The preceding summary of the present situation illustrates the limits of the infor- 
mation that can be obtained from studies with genetic recombinants in a fine- 
structure analysis of H-2. Clearly the development of strains carrying novel H-2 
haplotypes derived by point mutations from a well-characterized existing haplotype 
could further such analysis. However, in view of our considerable ignorance of the 
nature and mechanisms of mutagenesis in higher organisms, it seems advisable to 
investigate to what extent our concepts, derived from studies in bacteria and fungi, can 
be extrapolated to mammals. 
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Bailey et aL (1970), through skin grafting, discovered in a (C57BL/6 • BALB/c)F 1 
mouse a spontaneous mutation in the H-2b haplotype. The novel haplotype is 
designated H-2 ba and carried on a C57BL/6 (B6) background in the strain B6-C-H(zl) 
(short: H(zl), alternative designation B6.C-H-2aa). The mutant and B6 show strong 
reciprocal skin-graft rejection, and the mutation responsible for this incompatibility 
could, by complementation studies, be mapped into the K end of the H-2 complex. 
Nevertheless, the strains could not be distinguished serologically either by H-2 typing 
or by repeated attempts at reciprocal immunization (Bailey et al. 1970). Nor did a 
ratanti-B6 serum reveal any serological differences with H(zl) (M. Cherry and D. 
Bailey, personal communication). Widmer et  al. (1973)demonstrated strong bidirec- 
tional incompatibility with regard to both the mixed leucocyte reaction (MLR) and 
CML. This latter result, confirmed by us, presents a puzzle in that previous studies 
in various laboratories (Bach et al. 1972, Meo etal .  1973a, Nabholz et al. 1974, Alter 
et  al. 1973, Abbasi et  al. 1973) had provided strong evidence for genetic separation of 
CML- and MLR-determinants, a strong MLR-response being tied to incompatibiltiy 
within a segment of the/-region (Meo et  al. 1973b) not including H-2K. 
Therefore, both with regard to an understanding of mutational events in 
mammals, in general, as well as in the context of the fine structure analysis of the MHC, 
an attempt to map more precisely the mutational changes in H(zl) leading to MLR- and 
CML-incompatibility wi~ B6, respectively, seemed necessary. The present report con- 
tains results bearing on the location of the CML mutation in H(zl) as well as those of 
a study on cross-reactions between the new (private) CML specificity of H(z l )and  
(public) CML specificities of other H-2 haplotypes. 
Materials and Me thods  
Mice. Animals of the strains C57BL/6J (B6) and BALB/cJ as well as the F 1 
hybrids, B6 • A/J and BALB/c • B6, were obtained from the Roche animal colony in 
Fiillinsdorf. All other inbred strains are maintained as breeding stocks in the Human 
Genetics Department, Ann Arbor. For production, they are occasionally bred in the 
Basel Institute for Immunology. The original source of  most of these strains is listed in 
a previous publication (Meo et  al. 1973a). Strain B6.C-H(zl) was a gift of Donald W. 
Bailey, The Jackson Laboratory; strain AQR was a gift of Jan Klein, present address: 
Department of Microbiology, The University of Texas, Southwestern Medical School, 
Dallas, Texas. 
H-2 haplotypes of strains are indicated in terms of the allelic origins of the K,/ ,  
S, and D regions respectively. 
All experimental methods have been described in detail in a previous report 
(Nabholz et al. 1974). Briefly, they are as follows. 
Culture Conditions. Cells are cultured at 37~ in a humidified incubator 
supplied with a mixture of 95% air-5% CO2. 
Media. Culture medium is RPMI containing penicillin, streptomycin, additional 
glutamine, 30 mM HEPES, 3 • 10-s  M 2-mercaptoethanol, and 20% fetal calf serum. 
CML assays are carried out in similar medium, but without 2-mercaptoethanol 
and with only 10% fetal calf serum. 
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Mixed Leucocyte Cultures (MLC). To generate killer cells 107 responder 
cells (spleen) are cocultured for 5 days with 8 X 106 irradiated (3300 r) stimulator 
cells (spleen) in 4.5 ml medium in a 30-ml plastic culture flask (Falcon No. 3012) 
standing on its side. 
Targets. Target cell cultures (spleen) are set up on the same day as the 
MLC's. PHA (final conc. 1:100 stock solution of Difco PHA-M) is added on day 2. 
Cells are harvested on day 5, labeled for 3 hours with s 1Cr (500/aCi in. 3 ml containing 
5-10 • 106 cells), and washed twice. Viable cells are separated on a Ficoll-Urovison 
gradient and washed once more. 
CML-assay. The MLC's are spun down and the cells resuspended.to a 
constant volume so that each 150/al contain the descendants of 106 or 2 • 106 re- 
sponder cells. Two threefold serial dilutions are made. Targets are adjusted to a con- 
centration of, usually, 2 • 104 cells/50/al. One hundred-fifty microliters of  killer cell 
suspension and 50/al target cell suspension are added to the well of a round-bottomed 
microtest plate. Killing activity of each suspension is assayed in triplicate. The mixtures 
are spun gently for 2.5 minutes. After incubation for 4 hours at 37~ the plates are 
centrifuged again, 100/al of the supernatant are collected from each well, and 100tJl 
of a 10% Zaponin (Coulter Electronics) solution added to each well. After further 
incubation another 100 tal are harvested. 
In experiments involving the addition of antisera to killer/target mixtures, 
10tal of antiserum are added to the well first, then 50/al of killer cell suspension, and 
last, 25/al of target cells. The microtest plate is kept on ice during the addition of ceils 
and sera and not spun before incubation at 37~ One hundred microliters of PBS are 
added before the postincubation spin. The s tCr counts in the two samples obtained 
from each well are determined and used to calculate percent specific release = 
100 • (percent experimental release - percent spontaneous release) / (100 - percent 
spontaneous release) and standard deviations thereof. 
Antiserum Fractionation: In one experiment ammonium sulfate precipitates 
of antisera were used. The precipitates had been redissolved in, and extensively 
dialyzed against, phosphate buffered saline. 
Results 
Mapping the New Private CML Specificity Characteristic of  B6.C-H-2ba. 
a) Cross-reaction Between B6 and H(zl ). When B10.A (5R) responder cells (H-2 
haplotype: bbdd) are stimulated with B6 cells, the resulting killer cells display approxi- 
mately equal levels of lytic activity against B6, H(zl)  or A.BY targets (the last strain 
shares with B10 the H-2b haplotype) (Fig. 1). This is expected as the killer cells should 
be directed against the private CML specificity associated with the H-2D b region 
common to all three target strains. The specific lysis observed in this situation can be 
used as a standard to which lyric potentials of other responder/stimulator combinations 
on the same target cells are compared (see also Nabholz et al. 1974). Thus when cells 
from strain HTG (dddb) are stimulated with B6, the resulting killer cells are much 
more active against B6 and A.BY than against H(zl). The reverse result is obtained 
when H(zl)  is the stimulator of HTG. These results establish that the mutation(s) in 
H(zl) must have led to a change in the private K end CML specificity of B6, which, 
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by extrapolation from the earlier described work, is controlled by the H-2Kb allele or 
by a gene extremely closely linked to it. 
b) Inhibition of CML Between B6 and H(zl) by Specific Antisera. Previous 
work (Nabholz et aL 1974) had demonstrated that antisera could block CML only 
when they were directed, presumably, against the same H-2K or H-2D determinants 
as the killer cells. [Anti-H-2 sera directed against the responder cells have no detectable 
blocking activity, (Cerottini and Brunner 1973, Nabholz et al. 1974)]. In particular, 
killing directed against Kb-region CML determinants could be blocked by an anti-H-2.33 
serum [(B10.D2 X A)F 1 anti-HTI]. This inhibition did not interfere with killing 
directed against D end determinants on the same target cells. This is true even when 
both killer and target cell carry the Kb region (unpublished results). The same serum 
was able to completely block lysis of both B6 and H(zl) targets by HTG (dddb) 
r 
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Fig. 1. Cross-reactions in CML between B6, H(zl) and A.BY: The allelic origin of the K, / ,  S and 
D regions of the H-2 complex are indicated for HTG and B10.A (5R). Subscript T refers to targets. 
Ordinate: To each well the killer cells derived from a known number of responders are added, 
Number of responders/well: Exp. a: 0.11 X 106 and 0.33 X 106; Exp. b: 0.17 X 106 and 0.50 X 
106. Total 51Cr cpm and percent spontaneous release of targets (2 X 104): Exp. a: B6 :5252  
cpm, 35%, H(zl): 4805 cpm, 26%, A.BY: 4667 cpm, 20%; Exp. b: B6:31339  cpm, 48% H(zl): 
24958 cpm, 44%, A.BY: 23390 cpm, 38%. 
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cells st imulated with either strain (Table 1). In this study, an additional serum (a gift 
from S. Cullen and S. Nathenson) prepared by immunization of  HTG mice with cells 
from a B6 thymoma cell line, EL4, which does not express detectable Ia- ( immune 
response region associated) antigens, was used. The difference between the two sera 
lies in the fact that the anti-H-2.33 serum may, and probably does, contain anti-Ia 
antibodies (for review, see Shreffler and David 1974), while the latter,  in precipi tat ion 
analysis (Cullen et  al. 1974), does not  recognize Ia-specificities (S. Cullen and S. 
Nathenson, personal communication).  It may, on the other hand, have activity against 
some of  the public H-2Kb specificities. 
High concentrations of  these two sera completely abrogate specific cell lysis 
either by appropriately sensitized H(z l )  cells against B6 targets or in the reverse 
direction (Fig. 2a). Sodium sulfate fractionated antisera still give very strong inhibition 
(Fig. 2b). The degree of  inhibition can be assessed by comparing the specific lysis 
obtained in the presence of  antiserum to the dose-response curve resulting from 
variation of  the killer cell number. Thus, e.g., in the experiment shown in Fig. 2b, the 
highest concentration of  either fractionated antiserum reduces the specific release of  
B6 stimulated with and tested against H(z l )  to the level obtained with a 1:9 dilution 
of  the same killer, i.e., killing is inhibited by about 90%. 
In both  experiments inhibition by either antiserum of  B6 target cell lysis is 
significantly stronger than inhibition in the reverse direction. The results suggest the 
possibility that  the affinity of  blocking antibodies in these sera is somewhat less for 
H(z l )  than for B6. However, as we do not  know the kinetics o f  inhibition with regard 
to antisera concentration at different concentrations of  killer cells, we cannot 
interpret this observation with certainty. The cytotoxic i ty  titers of  the two antisera on 
B6 and H(zl) cells are not  significantly different. 
Table 1. Inhibition of CML Against K end CML Determinants of 
B6 and H(zl) with an Anti-H-2.33 Serum a 
Responder: HTG (dddb) 
No. of responders Serum Target 
Stimulator (• 10 -6)  (dilution) c B6 H(zl) 
B6 
H(zl) 
1.0 - 36 -+ 3 20 -+ 0 
.33 - 28 -+ 3 6 + 4 
.11 - 1 9  -+ 2 - 1  -+ 9 
1.0 1:17 -5  -+ 4 -5  + 3 
1.0 1:68 1 -+ 2 -4  _+ 1 
1.0 - 21 -+ 3 38 -+ 4 
.33 - 14 -+ 1 28 -+ 5 
.11 - 7 + 2 2 2  + 2 
1.0 1:17 1 + 0 -3  + 5 
1.0 1:68 7 + 0 9 -+ 4 
a(B10.D2 • A)F 1 anti-HTI. 
bH-2 haplotype of HTG in terms of allelic origins of K, L S and D regions. 
CFinal dilution of serum in assay mixture. 
Data are expressed as percent specific release (see Materials and Methods) 
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Analysis of Cross-reaction Between the New CML-specificity of  H(zl) and CML- 
Specificities ofOtherH-2Haplotypes. Widmer et al. (1973) had reported that B6 
stimulated with H(zl) was able to lyse also B10.BR (H-2k) cells to a considerable 
degree. Our own work hinted at the existence of cross-reactions detectable in CML 
(Nabholz et al. 1974) and subsequent analysis (manuscript in preparation) has revealed 
extensive but specific cross-reactivity in CML assays between different H-2 haplotypes, 
including cross-reaction between K and D end CML specificities. 
R: H(zl)  B6 
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Fig. 2. Inhibition of CML between B6 and H(zl) by anti-H-2 sera: Exp. a: complete sera; b: 
sodium sulfate fractionated sera. In both experiments a control for antibody dependent cell- 
mediated cell lysis was negative. O, 0: Reaction without serum at killer cell concentrations 
corresponding to 106, 0.33 • 106 and 0.11 • 106 (only exp. b)responders/well. All reactions in 
the presence of antisera involve the highest killer cell concentration (106 responders). D, =: 
Reaction in presence of anti-H-2.33 serum, zx, A: Reaction in presence of anti-EL4 serum. Targets: 
(cpm, percent spontaneous release). Exp. a: (1.25 X 104 cells): B6:14604 cpm, 55%; H(zl): 
12728 cpm, 54%. Exp. b: (1.5 • 104 cells): B6:6694 cpm, 45%; H(zl): 6645 cpm, 38%. 
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We have attempted to map some of the cross-reacting determinants detected by 
B6 when stimulated with B6.C-H(zl). The results of one particular experiment are 
illustrated in Fig. 3 and our findings are summarized in Table 2. 
It is clear that B6 stimulated with H(zl) reacts significantly against all tested 
strains except HTG. Comparing the 1-1-2 haplotypes of HTG (dddb), HTI (bbbd), and 
BALB/c (dddd) it is evident that at least one cross-reacting determinant is controlled 
by the H-2Da region. This cross-reaction is abrogated, as expected, by complement- 
ation with either A/J or BALB/c. Furthermore, although there is significant cross- 
reaction by B6 stimulated with H(zl) against BIO.A (2R) (kkdb),  it is much weaker 
than against B10.A (kkdd). This suggests that part of the latter cross-reaction is 
against determinants controlled by the K end of the H-2a haplotype. This interpreta- 
tion is supported by the fact that complementation with BALB/c reduces the cross- 
reaction against B10.A but not against B10.A (2R). That this cross-reacting specificity 
is controlled by the H-2Kk region follows from the fact that it is not present on cells 
of the strain AQR (qkdd). 
Discussion 
The results reported here establish that H(zl) carries a new private CML 
specificity controlled by the gene determining the private K end CML specificity 
of B6. Thus, from the previous genetic analyses of CML, we can extrapolate that the 
private CML specificity characteristic for H(zl) is controlled by a locus identical or 
very closely linked to H-2K. 
H(Zl)T , / t  
/r 
C . /  
9 / . / ,  . /  . / /  
9 
B6 T BALB/c T HTI T HTG T RESP.: STIM.: 
50[ dddd b / b d  dddb B6 H(zl) * 
9 B6 X BALB/c  H l z l )  9 
B6 B6 o 
B10.A T B10.A(2R) T A.TL T AQR T 
kkdd kkdb skkd qkdd 
Fig. 3. Cross-reactions in CML between H-2 ba and other H-2 haplotypes. For each target (sub- 
script T) the allelic origin of the K, I, S, and D regions of the H-2 complex are indicated. Killers 
are tested at concentrations.corresponding to 2.2 • 106, 0.7 • 106, and 0.2 • 106 responders/ 
well. Targets (2 • 104/well): cpm, percent spontaneous release: B6:4926 epm, 29%; H(zl): 
5970 cpm, 33%; HTG: 8232 cpm, 26%; BALB/c: 8142 cpm, 28%; B10.A (2R): 10246 cpm, 25%; 
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This interpretation is supported by the finding that both a monospecific H-2.33 
serum as well as the HTG-anti-EIA serum, can block the lyric reaction between B6 and 
H(zl) in either direction. Together the experiments suggest that the new private CML 
specificity of H(zl) is controlled by the H-2K locus itself. 
Two alternative explanations cannot be ruled out: a) The CML determinants 
may in fact be controlled by a locus not only very closely linked to the H-2K locus 
but the product of which also is on the cell surface physically linked to the H-2K gene 
product, recognized by the antisera, b) It is conceivable that the private K end CML 
determinants of B6 and H(zl) are controlled by genes of the I region (as the earlier 
genetic analyses of CML made this very unlikely for the available haplotypes resulting 
from crossovers between K and I regions, this would probably mean that CML 
determinants can be controlled by different loci in the different haplotypes and 
that the anti-EIA serum contains noncomplement fixing antibodies against these 
determinants). 
The cross-reaction analysis clearly demonstrates the existence of CML specificities 
shared by K and D end associated CML determinants, and that the cross-reacting 
specificities analysed so far map in the K and D regions themselves. The finding o f  K-D 
cross-reaction between a presumably novel CML specificity arisen by mutation and 
specificities controlled by existing K and D alleles suggests that such cross-reactions do 
not necessarily reflect the very "old" specificities that arose prior to the duplication 
event(s) that gave rise to the bipartite structure o f  H-2 (Klein and Shreffler 1970). 
If the mutation is in the H-2K locus then, not being detectable serologically, it 
presumably affects only a small part of the H-2 molecule. [One would then interpret 
the cross-reactions as an example of a "simplex-complex" situation, i.e., the cross- 
reactions are a result of similarities between the cross-reacting specificities and the 
new private CML specificity of H(zl)] .  
In any case the alteration must be in the site determining the private CML 
specificity of B6 and, presumably, the specificity responsible for the strong skin-graft 
rejection between B6 and H(zl). Thus, if the size of the T-cell receptor combining site 
is comparable to that of an antibody molecule, then the results suggest that the private 
CML-(T cell) and the private serological (B cell) specificities are not the same molecular 
sites, whether they are on the same molecule or not. Alternatively, one could envisage 
that the structure recognized by the T cell is much larger than that recognized by an 
antibody and that the unchanged private B cell specificity is a part of the private 
T cell specificity, but the only serologically recognizable one. Whatever the view on 
the nature of the T-cell receptor for histocompatibility determinants, the data reported 
here suggest that, as for soluble antigens (Hammerling and McDevitt 1974), T- and 
B-cell dictionaries for histocompatibility determinants are different. 
The results reported here do not resolve the puzzle presented by the observation 
that B6 and H(zl) are mutually incompatible with regard to both MLR and CML, 
while the determinants recognized by the two tests have genetically been separated 
and mapped into different parts of the K end of the H-2 complex using two different 
recombinants between H-2K and Ir- lA (Alter et al. 1973, Meo et al. 1973a, Nabholz 
et al. 1974, Abbasi et al. 1973). The most plausible explanations of this apparent 
inconsistency are: 
1. The H-2b haplotype is different from the previously analysed ones (k,s,q) with 
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regard to the distribution of MLC genes in that the H-2Kb locus (or the CML locus 
associated with it) controls a strong MLR determinant. This hypothesis is supported 
somewhat by the finding that anotherH-2b mutant derived from B6, M505, although 
different from H(zl), is incompatible with B6 both in MLR and CML (see 
accompanying paper by Forman and Klein). Alternatively, one might argue that the 
private K end CML specificity of B6 is controlled by the strong MLR determinant(s) 
in the I region, but the evidence suggesting that in the test described here, i.e., on 
PHA-stimulated target cells, no determinants controlled by I region loci are detected 
is quite strong. (On the other hand, recent experiments have, in fact, revealed that 
1 region-associated incompatibilities can be detected through skin grafting (Klein 
et al. 1974) and by killer cells generated in vitro when LPS-stimulated, instead of 
PHA-stimulated cells, are used as targets (M. Nabholz, et al. manuscript in prepara- 
tion)). 
2. According to the grid hypothesis (Boyse 1970, Ceppelim, 1970), a change in the 
H-2K locus could affect the expression of MLR determinants coded for by genes in 
the I region. There is no evidence supporting an interaction of this type, and earlier 
cited genetic analyses of MLR show that it is unlikely to be operative at least in the 
available relevant recombinants between H-2K and Ir-1. 
3. H(zl) differs from B6 not only in the H-2K but also in the I region-associated 
MLR-genes because of a second mutation that has occurred in the H-2ba 
chromosome. [No differences between B6 and H(zl)have been found in responsive- 
ness to a number of antigens, the response to which is under Ir-1 control (McDevitt, 
personal communication)]. The similarities between H(zl)  and M505 mentioned 
above would lead us to expect that the probability of such a second mutation leading 
to MLR incompatibility is not independent of the one detected by CML. 
Further genetic analysis of the MLR incompatibility between B6 and H(zl)  may 
help to distinguish between these alternatives, although most likely the final answer 
will depend on a biochemical characterization of the MHC products involved. 
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